Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

Completed · Phase 2

Conditions studied: Recurrent Adult Brain Tumor

In brief

RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving Gliadel wafer together with O6-benzylguanine works in treating patients with recurrent glioblastoma multiforme.

Key facts

Study ID

NCT00362921

Run by

Duke University

People needed

52

Starts

2004-04-01

Expected to finish

2008-07-01

Last updated by the study team

2014-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DISEASE CHARACTERISTICS-
• Histologically confirmed recurrent glioblastoma multiforme (including gliosarcoma) which can be confirmed, if not earlier, by intraoperative pathological diagnosis on frozen section
• Evidence of a unilateral, single focus of measurable Central Nervous System (CNS) neoplasm on contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan that is supratentorial and measures ≥ 1.0 cm in diameter
• PATIENT CHARACTERISTICS-
• Greater than or equal to 18 years old
• Life expectancy of greater than 12 weeks
• Karnofsky performance status greater than or equal to 60%
• Absolute neutrophil count ≥ 1,000/millimeters (mm)³
• Platelet count ≥ 100,000/mm³
• Total Serum Bilirubin < 2 times upper limit of normal (ULN)
• Serum glutamic oxaloacetic transaminase (SGOT) < 3 times ULN
• Blood urea nitrogen (BUN) < 1.5 times ULN
• Creatinine < 1.5 times ULN
• Negative pregnancy test
• Recovered from any effects of major surgery
• Patients or legal guardian must give written, informed consent.
• PRIOR CONCURRENT THERAPY-
• At least 2 weeks since prior surgical resection (if conducted) and recovered, unless there is unequivocal evidence of tumor progression
• At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas), unless there is unequivocal evidence of tumor progression.. However, patients treated with chemotherapeutic agents such as etoposide who would normally be retreated after shorter intervals (eg, 21 days on, 7 days off schedule) may be treated at the usual starting time even if less than 4 weeks from the last prior dose of chemotherapy.

You may not qualify if…

• Patients who have not recovered from surgery
• Patients who are not neurologically stable for 2 weeks prior to study entry
• Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics
• Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)
• Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
• Known HIV positivity or AIDS-related illness
• Pregnant or nursing women
• Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 24 hours prior to administration of study drug and be practicing medically approved contraceptive precautions.
• Men who are not advised to use an effective method of contraception
• Patients taking immuno-suppressive agents other than prescribed corticosteroids
• Patients who have had prior treatment with Gliadel Wafers.

Where it is running

• Duke Comprehensive Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.